---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-047188"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:37:03.622294+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vistagen appoints Paul Edick to Board of Directors, effective October 27, 2025

## Summary
- Mr. Edick appointed to Board, Audit Committee, and Compensation Committee.
- Received options to purchase 35,200 shares at $3.90/share (closing price on appointment date), vesting over 3 years.
- He is entitled to annual cash and equity compensation under the Director Compensation Plan.
- Mr. Edick is former Chairman/CEO of Xeris Pharmaceuticals and ex-CEO of Durata Therapeutics.
- No family relationships or transactions with the company requiring disclosure.

## SEC filing metadata
- accession: 0001628280-25-047188
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828025047188/0001628280-25-047188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828025047188/vtgn-20251027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-047188
- JSON: https://secwatch.observer/filing/0001628280-25-047188.json
- Plain text: https://secwatch.observer/filing/0001628280-25-047188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.